R&D channel feed – Endpoints News

R&D channel feed

Slammed by more deaths, Seattle Genetics scraps a PhIII study and pulls back (again) on vadastuximab

9 years ago

Clovis soars as a new round of PhIII Rubraca data looks promising — but roci scandal bites again with $142M settlement

9 years ago

Billionaire-backed Parker Institute tackles the Holy Grail of cancer R&D — with a virtual unknown

9 years ago

Looking to face down major league rivals, Novartis posts some impressive longterm data on Cosentyx

9 years ago

The myth of “leaner and meaner” pharma

9 years ago

After a sharp plunge, Epizyme bounces back on some bonny forecasts as shares go on a roller coaster ride

9 years ago

Opko insists that ‘outliers’ screwed up its big PhIII study on a Pfizer-partnered therapy

9 years ago

Epizyme shares slump as cancer drug data update disappoints

9 years ago

Aldeyra slides as lead drug flunks a primary endpoint in PhIIb

9 years ago

Jeffrey Kindler’s Centrexion spells out positive data for its PhIII-ready pain drug

9 years ago

Harvard researchers hope to bridge the protein gap with new institute

9 years ago

pSivida lines up EMA, FDA applications for eye drug/device as 2nd PhIII delivers positive data

9 years ago

J&J boasts improved cardio safety with SGLT2 franchise drug Invokana

9 years ago

Acceleron scraps dalantercept after it flunks a PhII test for kidney cancer

9 years ago

Merck halts enrollment on two PhIII Keytruda combo studies as outside monitors flag a worrying rate of deaths

9 years ago

AstraZeneca punts NASH drug from an ailing Regulus as their lead program goes under for the last time

9 years ago

Seres grabs $20M on PhIII microbiome launch

9 years ago

With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug

9 years ago

Merck, Pfizer make their PhIII case for an SGLT2 latecomer to the blockbuster showdown in diabetes

9 years ago

Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA

9 years ago

Trial observers say ‘game over’ for XBiotech's failed PhIII cancer study, the latest in a long line of setbacks

9 years ago

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?

9 years ago

Lexicon 3-for-3 in PhIII for a new diabetes pill, racking up a clean sweep under $1.7B Sanofi pact

9 years ago

Genentech axes its $1B-plus IDO drug deal with NewLink in the wake of underwhelming data

9 years ago

First page Previous page 299 300 301302303 304 305 Next page Last page